<ul><li>Zydus Lifesciences Ltd. reported Q4 growth with a 33.2% Ebitda margin increase year-on-year.</li><li>Despite positive numbers, Citi maintains a 'sell' rating due to concerns over earnings concentration in specific products.</li><li>US sales of Zydus Lifesciences reached $363 million, with quarterly growth possibly driven by generic Myrbetriq or Sitagliptin.</li><li>Citi highlights potential upside trends for Zydus shares but remains cautious about concentration risk in specific products and potential negative surprises.</li></ul>

Zydus Lifesciences Q4 Review: Citi Maintains 'Sell'; Sees Earnings Concentration In Specific Products

Discover more